Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Woohoo! another 9 more cents and I can sell at a 75% loss!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(144)
•••
Comment by unclepiemanon Aug 03, 2023 12:51am
89 Views
Post# 35570414

RE:RE:RE:RE:Woohoo! another 9 more cents and I can sell at a 75% loss!

RE:RE:RE:RE:Woohoo! another 9 more cents and I can sell at a 75% loss! correct, bankrupt. 

That's one way, but what if you have cap losses and don't want to trigger any capital gains to write anything off due to potential upcoming events where long-term holding will get you better results than selling only to re-buy and trigger a wash event... anyways. If you don't have capital gains to write it off against then you you are only limited to a % of the total lossess against your total income. The rule changes when the company goes under, I believe you are allowed to write off 100% of the lossess against your earned income. 

Not a tax or financial advice.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities